Is VRTX a good stock to buy? We came across a bullish thesis on Vertex Pharmaceuticals Incorporated on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on VRTX. Vertex Pharmaceuticals Incorporated’s share was trading at $445.77 as of June 9th. VRTX’s trailing and forward P/E were 26.46 and 23.47 respectively according to Yahoo Finance.
Pressmaster/Shutterstock.com
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. VRTX is being mispriced by the market, which continues to frame it narrowly as a high-quality but mature cystic fibrosis company, despite it evolving into a broader, pipeline-driven biotech with multiple late-stage growth drivers. The core cash engine remains its cystic fibrosis franchise, which targets the full spectrum of cystic fibrosis disease caused by CFTR gene mutations.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
This franchise, led by Trikafta, effectively treats the underlying biology of entire cystic fibrosis rather than just managing symptoms, resulting in near-monopoly positioning, exceptional durability, and long-duration recurring revenues as patients remain on therapy for life. This alone generates highly visible, high-margin cash flows that justify a substantial portion of Vertex’s valuation and give it a structurally advantaged funding base.
However, the bull case is increasingly driven by what this cash engine enables. Vertex has successfully used cystic fibrosis profits to fund a diversified pipeline, headlined by suzetrigine, a first-in-class non-opioid pain drug with a novel mechanism of action recently approved for acute pain.
This opens access to a massive and underpenetrated pain market, with meaningful upside optionality if development in chronic pain succeeds, significantly expanding the total addressable market. Beyond pain, Vertex is advancing programs in kidney disease, Type 1 diabetes through islet cell therapy collaboration, and AATD, several of which have Phase 3 readouts expected in 2026 and 2027, providing multiple near- to medium-term catalysts.
The market continues to value Vertex as if it is solely dependent on entire cystic fibrosis, ignoring the compounding optionality from its expanding pipeline. As these programs mature and clinical validation accumulates, the company’s earnings base, growth profile, and valuation multiple are likely to re-rate meaningfully. At current levels, Vertex offers a rare combination of dominant franchise cash flow, underappreciated pipeline depth, and asymmetric long-term upside.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy commercialization and pipeline optionality in gene editing and oncology. CRSP’s stock price has appreciated by approximately 25.65% since our coverage. Variant_Invest shares a similar view but emphasizes Vertex Pharmaceuticals Incorporated (VRTX) and its cystic fibrosis cash engine funding diversified late-stage pipeline catalysts, highlighting a broader reinvestment-driven biotech model.
Vertex Pharmaceuticals Incorporated is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 68 hedge fund portfolios held VRTX at the end of the first quarter which was 64 in the previous quarter. While we acknowledge the risk and potential of VRTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
